<--- Back to Details
First PageDocument Content
Rare diseases / Nociception / Glycogen storage disease type II / Hepatology / Acid alpha-glucosidase / Fabry disease / Lysosomal storage disease / Chronic pain / Medicine / Health / Pain
Date: 2013-08-24 22:34:38
Rare diseases
Nociception
Glycogen storage disease type II
Hepatology
Acid alpha-glucosidase
Fabry disease
Lysosomal storage disease
Chronic pain
Medicine
Health
Pain

Pain in adult patients with Pompe disease

Add to Reading List

Source URL: amdapompe.ehclients.com

Download Document from Source Website

File Size: 436,89 KB

Share Document on Facebook

Similar Documents

Medicine / Health / Clinical medicine / Rare diseases / Porphyrias / Lysosomal storage diseases / RTT / Erythropoietic protoporphyria / Glycogen storage disease type II / Disease

How one patient with a rare disease coped with his genetic disorder

DocID: 1r9mW - View Document

Clinical medicine / Neurochemistry / Medicine / Sodium channel blockers / Alglucosidase alfa / Calcium channel blockers / Glycogen storage disease type II / Ketamine / Treprostinil / Eptifibatide

LUMIZYME (alglucosidase alfa) for Injection

DocID: 1qeuI - View Document

United States patent law / BioMarin Pharmaceutical / Genzyme / Glycogen storage disease type II / Inter partes review / Pharmaceutical drug / Reexamination / Patent Trial and Appeal Board / Inter partes / Iduronidase

United States Court of Appeals for the Federal Circuit ______________________ GENZYME THERAPEUTIC PRODUCTS LIMITED PARTNERSHIP,

DocID: 1oYEH - View Document

Pompe  disease  (Glycogen  storage  disease  type  II) Glycogen  storage  disease  type  II  is  also  known  as  acid  maltase  deficiency  or  generalized  gl

DocID: 1lJGD - View Document

Genetic genealogy / BioMarin Pharmaceutical / Glycogen storage disease type II / Acid alpha-glucosidase / Lysosomal storage disease / Mucopolysaccharidosis / Alglucosidase alfa / Neuronal ceroid lipofuscinosis / Tetrahydrobiopterin / Health / Rare diseases / Medicine

May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im

DocID: 1aiEg - View Document